Cognition - OtherNCT07320300
Post Stroke Cognitive Impairment
An observational study of Cognition - Other, run by Assiut University.
Trial summary
clinical evaluation of the prevalence and severity of cognitive impairment among patients after ischemic and haemorrhagic stroke admitted to the Neuropsychiatry department Read more about this study
- Who is it for?
- Ages 18 to 60 years
- Conditions the study is for
- Cognition - Other
- What is being tested?
- Cognitive assessment: Montreal Cognitive Assessment (MoCA), Cognitive Assessment for Stroke patients, Oxford cognitive screening, Trail Making Test B, Digit Span-Backward, verbal fluency, Clinical Dem
- How many people
- 400 participants
- Where
- No sites listed yet
- Study dates
- Jan 2026to Dec 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 60 years
- All sexes
- Adult
Study population: egyptian population
Who may be able to join
- Patients of both sexes, aged 18- 60 years, with a history of first stroke within 3 months of admission, all types of stroke confirmed by imaging (ischemia, parenchymal haemorrhage, subarachnoid haemorrhage, venous stroke)
Who cannot join
- Age above 60 years, refusal to participate in the study, pre-existing dementia or significant psychiatric illness, severe aphasia or communication deficits precluding cognitive testing or severe comorbid condition limiting follow-ups, systemic diseases that are known to affect the central nervous system, such as (thyroid dysfunction, chronic infections, or system failure like liver or renal failure), significant sensory impairment (deafness and blindness), history of malignancy and those who have had neurosurgical procedures or severe head trauma at any time before a stroke.
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
Official title: Evaluation of Post-Stroke Cognitive Impairment in Patients Attending the Neuropsychiatry Department- Assiut University
clinical evaluation of the prevalence and severity of cognitive impairment among patients after ischemic and haemorrhagic stroke admitted to the Neuropsychiatry department
- Conditions
- Cognition - Other
- Being tested
- Cognitive assessment: Montreal Cognitive Assessment (MoCA), Cognitive Assessment for Stroke patients, Oxford cognitive screening, Trail Making Test B, Digit Span-Backward, verbal fluency, Clinical Dem
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Cognitive assessment: Montreal Cognitive Assessment (MoCA), Cognitive Assessment for Stroke patients, Oxford cognitive screening, Trail Making Test B, Digit Span-Backward, verbal fluency, Clinical DemOther
Follow-up: for cognitive and functional reassessment
What is being measured
The primary outcome is the main question the study is designed to answer.
the prevalence of cognitive impairment among patients after ischemic and haemorrhagic stroke admitted to the Neuropsychiatry department
clinical evaluation of the prevalence of cognitive impairment among patients after ischemic and haemorrhagic stroke admitted to the Neuropsychiatry departmen
Measured: baseline
prevalence estimates of PSCI within the stroke population admitted to a tertiary hospital.
Measured: baseline
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Jan 2026
- Study startJan 2026 (estimated)
- Primary completionNov 2027 (estimated)
- Study completionDec 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Cognition - OtherStudies of the same condition, open and under way.
- More trials run by Assiut UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 400 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Assiut University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Kamal Eldin Mohamed Ali Ahmed, Assiut University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07320300
- Sponsor's protocol ID
- post stroke cognition
- Status last verified
- Dec 2025
- First submitted
- 22 Nov 2025
- Last updated
- 6 Jan 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 6 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluation of Post-Stroke Cognitive Impairment in Patients Attending the Neuropsychiatry Department- Assiut University
- ClinicalTrials.gov ID
- NCT07320300
- Acronym / sponsor ID
- post stroke cognition
- Conditions
- Cognition - Other
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 400 participants (estimated)
- Lead sponsor
- Assiut UniversityUniversity, hospital or other
- Study start
- Jan 2026 (estimated)
- Primary completion
- Nov 2027 (estimated)
- Study completion
- Dec 2027 (estimated)
- First posted
- 6 Jan 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
clinical evaluation of the prevalence and severity of cognitive impairment among patients after ischemic and haemorrhagic stroke admitted to the Neuropsychiatry department
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 to 60 years
- Sex
- All
- Age groups
- Adult
- Study population
- egyptian population
Key inclusion criteria (1 listed)
- Patients of both sexes, aged 18- 60 years, with a history of first stroke within 3 months of admission, all types of stroke confirmed by imaging (ischemia, parenchymal haemorrhage, subarachnoid haemorrhage, venous stroke)
Key exclusion criteria (1 listed)
- Age above 60 years, refusal to participate in the study, pre-existing dementia or significant psychiatric illness, severe aphasia or communication deficits precluding cognitive testing or severe comorbid condition limiting follow-ups, systemic diseases that are known to affect the central nervous system, such as (thyroid dysfunction, chronic infections, or system failure like liver or renal failure), significant sensory impairment (deafness and blindness), history of malignancy and those who have had neurosurgical procedures or severe head trauma at any time before a stroke.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Cognitive assessment: Montreal Cognitive Assessment (MoCA), Cognitive Assessment for Stroke patients, Oxford cognitive screening, Trail Making Test B, Digit Span-Backward, verbal fluency, Clinical DemFollow-up: for cognitive and functional reassessment | Other | – |
Primary outcome
the prevalence of cognitive impairment among patients after ischemic and haemorrhagic stroke admitted to the Neuropsychiatry department
Time frame: baseline
clinical evaluation of the prevalence of cognitive impairment among patients after ischemic and haemorrhagic stroke admitted to the Neuropsychiatry departmen
prevalence estimates of PSCI within the stroke population admitted to a tertiary hospital.
Time frame: baseline
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Jan 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Cognition - Other
RecruitingObservational study
InRAD Observational Study
Alzheimer's Disease(AD), Mild Cognitive Impairment (MCI)
Not yet recruitingPhase 2
An Investigation of Mechanisms That Underly Paranoia in Behaviour and Brain That Can Inform Clinical Diagnoses That Include Paranoid Symptoms.
None Volunteer
Recruiting
iTBS to Enhance Social Cognition in People With Psychosis
Schizophrenia, Schizo Affective Disorder
Recruiting
Epigenetic Enhancement of Cognitive Training in Aging Mood and Schizophrenia Spectrum Disorder Populations
Bipolar Disorder (BD), Depression - Major Depressive Disorder
Not yet recruiting
WB-EMS Combined With Nutritional Guidance for a High-Protein Diet on Body Composition, Muscle Function, Psychological and Functional Outcomes in Older Adults With Excess Adiposity
Overweight (BMI > 25), Obesity & Overweight
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Questions about this trial
What is this clinical trial studying?
An observational study of Cognition - Other, run by Assiut University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 6 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact kamal eldin Mohamed (0201003983057, Kamal.17289724@med.aun.edu.eg), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
the prevalence of cognitive impairment among patients after ischemic and haemorrhagic stroke admitted to the Neuropsychiatry department (time frame: baseline). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Jan 2026.